These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28673340)

  • 1. Anti-citrullinated protein antibodies and bone loss in patients with early arthritis: comment on the article "Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis" by Bugatti et al.
    Castañeda S; Llorente I; García-Vicuña R; González-Álvaro I
    Arthritis Res Ther; 2017 Jul; 19(1):152. PubMed ID: 28673340
    [No Abstract]   [Full Text] [Related]  

  • 2. Are Rheumatoid Factor, Anti-Citrullinated Protein Antibodies, and Anti-Carbamylated Protein Antibodies Linked by Posttranslational Modification of IgG? Comment on the Article by Koppejan et al.
    Hutchinson D; Murphy D; Clarke A; Eggleton P
    Arthritis Rheumatol; 2016 Nov; 68(11):2825-2826. PubMed ID: 27483211
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis.
    Bugatti S; Bogliolo L; Vitolo B; Manzo A; Montecucco C; Caporali R
    Arthritis Res Ther; 2016 Oct; 18(1):226. PubMed ID: 27716332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year progression of erosive disease in patients with anti-citrullinated peptide antibodies and arthralgia.
    Keller KK; Thomsen JS; Stengaard-Pedersen K; Therkildsen J; Nielsen AW; Schiøtz-Christensen B; Svendsen L; Graakjær M; Petersen PM; Unger B; Kjær SG; Langdahl BL; Hauge EM
    Joint Bone Spine; 2020 Mar; 87(2):181-183. PubMed ID: 31521790
    [No Abstract]   [Full Text] [Related]  

  • 5. Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study.
    van Wesemael TJ; Ajeganova S; Humphreys J; Terao C; Muhammad A; Symmons DP; MacGregor AJ; Hafström I; Trouw LA; van der Helm-van Mil AH; Huizinga TW; Mimori T; Toes RE; Matsuda F; Svensson B; Verstappen SM; van der Woude D
    Arthritis Res Ther; 2016 Dec; 18(1):285. PubMed ID: 27906045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
    Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
    Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periarticular Bone Loss in Arthritis Is Induced by Autoantibodies Against Citrullinated Vimentin.
    Engdahl C; Bang H; Dietel K; Lang SC; Harre U; Schett G
    J Bone Miner Res; 2017 Aug; 32(8):1681-1691. PubMed ID: 28425620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expert consensus on clinical detection of rheumatoid arthritis related autoantibodies].
    ; ;
    Zhonghua Nei Ke Za Zhi; 2021 Jun; 60(6):516-521. PubMed ID: 34058807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive.
    Hiwa R; Ohmura K; Nakabo S; Terao C; Murakami K; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Hashimoto M; Furu M; Ito H; Fujii T; Mimori T
    Int J Rheum Dis; 2017 Jun; 20(6):731-736. PubMed ID: 28198158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the diagnostic potential of three anti-citrullinated protein antibodies as adjuncts to rheumatoid factor and CCP in a cohort of South African rheumatoid arthritis patients.
    Meyer PWA; Ally MTM; Hodkinson B; Anderson R; Tikly M
    Rheumatol Int; 2018 Jun; 38(6):993-1001. PubMed ID: 29713794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of ACPAs in at-risk individuals: Early targeting of the bone and joints.
    Schett G
    Best Pract Res Clin Rheumatol; 2017 Feb; 31(1):53-58. PubMed ID: 29221598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmunity to citrullinated type II collagen in rheumatoid arthritis.
    Yoshida M; Tsuji M; Kurosaka D; Kurosaka D; Yasuda J; Ito Y; Nishizawa T; Yamada A
    Mod Rheumatol; 2006; 16(5):276-81. PubMed ID: 17039307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-citrullinated protein antibodies and their clinical utility in rheumatoid arthritis.
    Farid SSh; Azizi G; Mirshafiey A
    Int J Rheum Dis; 2013 Aug; 16(4):379-86. PubMed ID: 23992255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Specificity of Monoclonal Anti-Citrullinated Protein Antibodies: Comment on the Article by Steen et al.
    Holmdahl R
    Arthritis Rheumatol; 2019 Feb; 71(2):324-325. PubMed ID: 30303300
    [No Abstract]   [Full Text] [Related]  

  • 15. Tocilizumab reduced production of systemic sclerosis-related autoantibodies and anti-cyclic citrullinated protein antibodies in two patients with overlapping systemic sclerosis and rheumatoid arthritis.
    Kono M; Yasuda S; Kono M; Atsumi T
    Scand J Rheumatol; 2018 May; 47(3):248-250. PubMed ID: 28480784
    [No Abstract]   [Full Text] [Related]  

  • 16. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies against citrullinated histone H3 in rheumatoid arthritis and periodontitis patients.
    Janssen KMJ; de Smit MJ; Withaar C; Brouwer E; van Winkelhoff AJ; Vissink A; Westra J
    J Clin Periodontol; 2017 Jun; 44(6):577-584. PubMed ID: 28370244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study.
    Berendsen MLT; van Maaren MC; Arts EEA; den Broeder AA; Popa CD; Fransen J
    J Rheumatol; 2017 Sep; 44(9):1325-1330. PubMed ID: 28668802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.
    Alemao E; Guo Z; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME
    Semin Arthritis Rheum; 2018 Apr; 47(5):630-638. PubMed ID: 29241640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
    Vis M; Bos WH; Wolbink G; Voskuyl AE; Twisk JW; Van de Stadt R; Hamann D; Dijkmans BA; Lems WF
    J Rheumatol; 2008 Mar; 35(3):425-8. PubMed ID: 18322974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.